AARDEX Group Partners with Industry Leaders on DiMe’s V3+ Framework Project to Enhance Usability of DHTs

AARDEX Group Partners with Industry Leaders on DiMe’s V3+ Framework Project to Enhance Usability of DHTs Extending the Verification, Analytical Validation, and Clinical Validation (V3+) Framework Project will ensure digital clinical measures and products meet the needs of larger audiences.

Qlucore launches new Omics Explorer version - up to 900 times faster

Nasdaq First North-listed Qlucore, leading software provider of visualization-based software for research-oriented data analysis and precision diagnostics, has launched Qlucore Omics Explorer (QOE) version 3.9. The new version provides statistical test results up to 900 times faster.

Clearwater Launches New Branding and Website Affirming its Continued Commitment to Serving the Cybersecurity and Compliance Needs of the Healthcare Industry

Clearwater today launched a new website and brand identity to reflect the company’s mission of serving the needs of the entire healthcare ecosystem following its acquisitions of TECH LOCK and CynergisTek. It’s no secret that healthcare organizations need a strong cybersecurity and compliance partner now more than ever, and the combined company provides a deep pool of experts across a broad range of cybersecurity, privacy, and compliance domains.

CluePoints Supports Launch of RBQM Live 2023 as Premier Event Sponsor

CluePoints Supports Launch of RBQM Live 2023 as Premier Event Sponsor Registration for must-attend Risk-Based Quality Management event is now open

Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics

Arranta Bio, part of Recipharm’s biologics business, has signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics.

2bPrecise Named “Best Overall Genomics Company” by MedTech Breakthrough

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies

FDB Vela™ Leader to Share Vision for Vastly Reducing Fill Times for Specialty Drug ePrescribing at NCPDP Annual Conference

FDB Vela™ Leader to Share Vision for Vastly Reducing Fill Times for Specialty Drug ePrescribing at NCPDP Annual Conference

BOC Sciences Reports Strong Capabilities of CDMO Operations

BOC Sciences, one of the front-runners in chemical material manufacturing and custom services for the full drug product lifecycle, today reported strong growth over the past year in its expanded contract development and manufacturing (CDMO) platform.

New Talent Equity® Report shows how life sciences organisations are using hybrid working to their advantage

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: No turning back – an analysis of the hybrid working models that have emerged from the pandemic and how they have enabled positive changes to leadership, team dynamics and recruitment and retention of talent in the life science sector.

MultiOmic Health closes $6.2 million funding round to discover precision medicines for metabolic syndrome-related conditions

MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, has closed a £5 million (US$6.2 million) seed funding extension round to build its precision therapeutics discovery platform for metabolic syndrome-related medical conditions.

BOC Sciences Ensures Secure and Rapid Delivery of Isotopically Labeled Materials for Drug Compound Development

BOC Sciences' radiochemists work closely with the worldwide drug compound research teams to deliver high-quality stable isotope labeled products as well as consulting and tailor-made services.

It Turns out that p53 is Destroyed in a Whole New Way

CSHL scientists have discovered that a protein called BRD8 goes out of control in glioblastoma, paralyzing P53. The discovery could help turn this deadly cancer into a treatable disease.

Crispr/Cas9 Platform Developed Maize Mutant Library Covering 800 Functional Genes with CRISPR/Cas9 Technology

Microbialtec Utilized Two Methods to Achieve Pseudomonas Aeruginosa Genome Editin

Microbiosci Has Established Automated Microbial Strains Breeding and Screening Platform

Form Bio joins PacBio Compatible Program to Accelerate Gene Therapy Research from Data to Insights

Form Bio, the provider of advanced computational life sciences technology today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as compatible with PacBio’s HiFi sequencing solutions, empowering corporate and academic research teams with a dramatically streamlined path from HiFi read data to breakthrough insights.

Form Bio joins PacBio Compatible Program to Accelerate Gene Therapy Research from Data to Insights

Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With an accessible, comprehensive and collaborative platform, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. For more information on Form Bio, visit www.formbio.com

Integrated DNA Technologies Launches New Archer™ FUSIONPlex™ Core Solid Tumor Panel for Cancer Research

New panel leverages Anchored Multiplex PCR (AMP™) chemistry and Archer Analysis to detect fusions, splice variants and more, enabling downstream application of precision medicine

Patent Issued for AI-Enabled Predictive Risk Rating Capability of Clearwater’s IRM|Analysis® Software

Innovative Application of Artificial Intelligence and Machine Learning Gives Healthcare Organizations Additional Capabilities to Stop Threat Actors by Enabling Them to Make Better Cyber Risk Decisions

CureSearch to fund new cutting-edge study for rare blood cancer in children

Elvin Wagenblast, PhD, of The Tisch Cancer Institute at Mount Sinai, received a CureSearch Young Investigator Award to develop a better understanding of AML in order to guide treatment for patients where standard chemotherapy is ineffective. The study is investigating how a normal blood stem cell can become cancerous. Dr. Wagenblast’s team is using state-of-the-art genome editing to understand vulnerabilities of the disease like never before.